Mainz Biomed Announces Pricing of $3.0 Million Follow-On Offering of Ordinary Shares and Warrants

Rhea-AI Summary

Mainz Biomed (NASDAQ:MYNZ), a molecular genetics diagnostic company focused on early cancer detection, has announced the pricing of a $3.0 million follow-on offering. The offering consists of 2,222,222 units priced at $1.35 per unit, with each unit including one ordinary share (or pre-funded warrant) and one Series A warrant.

The Series A warrants will be immediately exercisable at $1.35 per share with a five-year expiration term. Maxim Group LLC serves as the sole placement agent, with the offering expected to close around August 5, 2025, subject to customary conditions.

Positive

• Warrants provide potential for additional future funding through exercise
• Successful registration and SEC approval of Form F-1

Negative

• Small offering size of only $3.0 million indicates limited funding raised
• Potential dilution for existing shareholders
• Low unit pricing at $1.35 may indicate weak market conditions

Insights

Financial Analyst

Mainz Biomed's $3M offering dilutes shareholders while providing minimal runway extension, suggesting urgent capital needs.

Mainz Biomed's announcement of a $3 million follow-on offering signals significant financial pressure for this molecular diagnostic company. The structure of this capital raise – combining ordinary shares with warrants at $1.35 per unit – reveals concerning dynamics. First, the modest size of this offering indicates it likely provides minimal operational runway for a biotech company developing diagnostic products. Each unit includes one ordinary share plus one Series A warrant to purchase 1.5 additional shares, creating potential for substantial future dilution beyond the initial 2,222,222 units being sold.

The warrant exercise price of $1.35 matches the offering price, providing no premium, which typically indicates weak negotiating position. This suggests institutional investors demanded full warrant coverage at current market prices to participate. The five-year warrant duration further suggests investors sought significant upside protection given perceived risks. Maxim Group's role as sole placement agent, rather than a syndicate of multiple banks, indicates limited market interest.

This financing follows a clear pattern in the micro-cap biotech sector where companies facing cash constraints must accept increasingly dilutive terms. For diagnostic companies with high development and commercialization costs, $3 million represents a minimal capital infusion that likely addresses immediate liquidity needs rather than providing long-term stability. The timing of this offering and its structure suggests management is operating with limited financial flexibility, potentially impacting operational decisions and commercial strategy going forward.

BERKELEY, Calif. and MAINZ, Germany, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, today announced the pricing of a follow-on offering of 2,222,222 units, with each unit consisting of one ordinary share (or pre-funded warrant in lieu thereof) and one Series A warrant to purchase one and one half ordinary shares for gross proceeds of approximately $3.0 million. Each unit is being sold at an effective offering price of $1.35 per unit. Each Series A warrant will be immediately exercisable at an exercise price of $1.35 per share and will expire five years from the date of issuance.

Maxim Group LLC is acting as the sole placement agent for the offering. The offering is expected to close on or about August 5, 2025, subject to customary closing conditions.

The newly issued securities described above are being offered pursuant to a registration statement on Form F-1, as amended (File No. 333-289095) (the “Registration Statement”), which was declared effective by the Securities and Exchange Commission (the “SEC”) on August 4, 2025. The offering is being made only by means of a prospectus which is a part of the Registration Statement. A final prospectus relating to the offering will be filed with the SEC. Copies of the final prospectus relating to this offering may be obtained from Maxim Group LLC, 300 Park Avenue, 16th Floor, New York, NY 10022, at (212) 895-3745. This press release shall not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

Please visit Mainz Biomed’s official website for investors at mainzbiomed.com/investors/ for more information

About Mainz Biomed NV

Mainz Biomed develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The Company’s flagship product is ColoAlert®, an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer. ColoAlert® is marketed across Europe. The Company is currently running a clinical study to prepare for its pivotal FDA clinical study and US regulatory approval. Mainz Biomed’s product candidate portfolio also includes PancAlert, an early-stage pancreatic cancer screening test based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. To learn more, visit mainzbiomed.com.

For media inquiries

MC Services AG
Maximilian Schur / Simone Neeten
+49 211 529252 20
mainzbiomed@mc-services.eu

For investor inquiries, please contact info@mainzbiomed.com

Forward-Looking Statements

Certain statements made in this press release are “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “anticipate”, “believe”, “expect”, “estimate”, “plan”, “outlook”, and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements reflect the current analysis of existing information and are subject to various risks and uncertainties. As a result, caution must be exercised in relying on forward-looking statements. Due to known and unknown risks, actual results may differ materially from the Company’s expectations or projections. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: (i) the failure to meet projected development and related targets; (ii) changes in applicable laws or regulations; (iii) the effect of the COVID-19 pandemic on the Company and its current or intended markets; and (iv) other risks and uncertainties described herein, as well as those risks and uncertainties discussed from time to time in other reports and other public filings with the Securities and Exchange Commission (the “SEC”) by the Company. Additional information concerning these and other factors that may impact the Company’s expectations and projections can be found in its initial filings with the SEC, including its annual report on Form 20-F filed on March 31, 2025. The Company’s SEC filings are available publicly on the SEC’s website at www.sec.gov. Any forward-looking statement made by us in this press release is based only on information currently available to Mainz Biomed and speaks only as of the date on which it is made. Mainz Biomed undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise, except as required by law.

FAQ

What is the size and price of Mainz Biomed's (MYNZ) follow-on offering in August 2025?

Mainz Biomed announced a $3.0 million follow-on offering consisting of 2,222,222 units priced at $1.35 per unit.

What does each unit in MYNZ's offering include?

Each unit includes one ordinary share (or pre-funded warrant) and one Series A warrant to purchase one and one half ordinary shares.

What are the terms of MYNZ's Series A warrants?

The Series A warrants are immediately exercisable at $1.35 per share and will expire five years from the issuance date.

When is MYNZ's follow-on offering expected to close?

The offering is expected to close on or about August 5, 2025, subject to customary closing conditions.

Who is the placement agent for Mainz Biomed's offering?

Maxim Group LLC is acting as the sole placement agent for the offering.